WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573297
CAS#: 1610007-47-0 (choline)
Description: YM-543, also known as ASP-543, is a selective SGLT2 inhibitor. Sodium-glucose cotransporter 2 (SGLT2) is a specifically expressed transporter in the kidney that plays an important role in renal glucose reabsorption, and its inhibition may present a novel therapeutic strategy for treating diabetes. YM543 potently and selectively inhibited mouse and human SGLT2 activities at nanomolar ranges. In vivo single oral administration of YM543 dose-dependently and significantly reduced blood glucose levels and improved glucose tolerance with a concomitant increase in urinary glucose excretion in KK/Ay type 2 diabetic mice, effects that were sustained even after 12 h.
MedKoo Cat#: 573297
Name: YM-543 choline
CAS#: 1610007-47-0 (choline)
Chemical Formula: C28H37NO7
Exact Mass: 499.257
Molecular Weight: 499.6
Elemental Analysis: C, 67.31; H, 7.47; N, 2.80; O, 22.42
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 918802-70-7 (choline) 918802-69-4 (anion) 655237-16-4 (free base) 1610007-47-0 (choline)
Synonym: ASP-543; ASP 543; ASP543; YM 543, YM-543, YM543
IUPAC/Chemical Name: 2-(trimethylammonio)ethan-1-olate compound with (2S,3R,4R,5S,6R)-2-(5-(azulen-2-ylmethyl)-2-hydroxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (1:1)
InChi Key: UNYLGPCKUYMDOB-NGOMLPPMSA-N
InChi Code: InChI=1S/C23H24O6.C5H13NO/c24-12-19-20(26)21(27)22(28)23(29-19)17-11-13(6-7-18(17)25)8-14-9-15-4-2-1-3-5-16(15)10-14;1-6(2,3)4-5-7/h1-7,9-11,19-28H,8,12H2;4-5H2,1-3H3/t19-,20-,21+,22-,23+;/m1./s1
SMILES Code: C[N+](C)(C)CC[O-].OC1=CC=C(CC2=CC3=CC=CC=CC3=C2)C=C1[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 499.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Nakada N. Evaluation of the Utility of Chimeric Mice with Humanized Livers for the Characterization and Profiling of the Metabolites of a Selective Inhibitor (YM543) of the Sodium-Glucose Cotransporter 2. Pharm Res. 2017 Apr;34(4):874-886. doi: 10.1007/s11095-017-2116-4. Epub 2017 Feb 13. PubMed PMID: 28194636.
2: Ikegai K, Imamura M, Suzuki T, Nakanishi K, Murakami T, Kurosaki E, Noda A, Kobayashi Y, Yokota M, Koide T, Kosakai K, Ohkura Y, Takeuchi M, Tomiyama H, Ohta M. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543. Bioorg Med Chem. 2013 Jul 1;21(13):3934-48. doi: 10.1016/j.bmc.2013.03.067. Epub 2013 Apr 10. PubMed PMID: 23651509.
3: Yokono M, Tahara A, Kurosaki E, Yamajuku D, Kihara R, Imamura M, Tomiyama H, Kobayashi Y, Noda A, Shibasaki M. Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Feb 1. [Epub ahead of print] PubMed PMID: 23374077.
